Tyra Biosciences is an oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Co. is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR family. Co.'s lead product candidate, TYRA-300, is designed to selectively inhibit Fibroblast Growth Factor Receptor3, with an initial focus on patients with bladder cancer. In addition, Co. has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase, and FGFR4-related cancers. The TYRA YTD return is shown above.
The YTD Return on the TYRA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether TYRA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TYRA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|